Overview
- The case report, published in Frontiers in Neuroscience, describes an anonymized 80‑year‑old woman with about 10 years of Alzheimer’s who received a 5‑gram dose of psilocybin mushrooms and showed surprising functional gains in the days that followed.
- Shortly after the first dose the patient had intense autonomic reactions and a long sleep‑like state, then about 19 hours later she began hours‑long autobiographical conversation and over subsequent days regained continence, better walking, dressing ability and social engagement.
- One month later the patient received a second, smaller 3‑gram dose and the authors report further verbal expressiveness and mobility improvements during that session.
- Authors and outside experts stress major limitations: the report is a single uncontrolled case without brain scans, biomarker confirmation, standardized cognitive testing, or formal ethics approval, so it cannot prove causation.
- Scientists propose a mechanism involving psilocybin’s action at 5‑HT2A serotonin receptors that can reorganize brain network connectivity and boost plasticity, and they urge carefully designed clinical trials rather than unsupervised use, noting serious safety risks for frail older adults.